Observational studyBMC cancer2026
Real-world evidence on second line chemotherapy in advanced biliary tract carcinoma refractory to gemcitabine and oxaliplatin (GemOx).
Observational study in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdvanced biliary tract carcinoma (aBTC) comes with poor prognosis. Gemcitabine with oxaliplatin (GemOx) has emerged as a pragmatic alternative to gemcitabine with cisplatin and has been a preferred first line palliative option at many centres around the world. The evidence on second line chemotherapy following treatment failure of GemOx is scarce.
methodsA retrospective multicentre cohort study in the Southeast healthcare region of Sweden, covering nine years (2011-2020) and three hospitals, was conducted. All patients with aBTC who had received first line GemOx and any second line treatment thereafter were included. Treatment patterns and clinicopathological prognostic parameters were explored.
resultsIn a cohort of 121 patients with aBTC who had received GemOx in the first line setting, 57 (47%) had proceeded to any type of second line systemic therapy and were included in this study. The most used regimen was capecitabine single agent in 37 (64.9%) patients followed by intravenous 5-FU (9, 15.8%). Median overall survival (OS) in the total cohort was 4.1 months (95% CI 3.2-5.0). Six- and twelve-month survival rates were 35.6% and 18.6%. Median time to treatment failure (TTF) was 1.8 months (95% CI 1.5-2.2). Performance status (PS) 2, according to Eastern Cooperative Oncology Group (ECOG), was an independent predictor for poor OS and TTF. Progression free survival (PFS) of < 6 months during first line treatment and extrahepatic localisation were independent predictors for poor OS. A nomogram was established using ECOG PS, 1st line PFS and primary tumour site. An exploratory prognostic model showed that patients with high total score in the nomogram had OS of 2.9 months compared to 4.3 months in patients with intermediate score and 13.1 months in patients with low score.
conclusionPatients with aBTC receiving second line chemotherapy following first line GemOx have very dismal prognosis. PS 0-1, first line PFS ≥ 6 months and intrahepatic disease localisation indicate better prognosis. These data highlight the need for improved and personalised treatment strategies in refractory aBTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.